Skip to main content

Advertisement

SpringerLink
Log in

Adipose Tissue: The New Endocrine Organ? A Review Article

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Fat is either white or brown, the latter being found principally in neonates. White fat, which comprises adipocytes, pre-adipocytes, macrophages, endothelial cells, fibroblasts, and leukocytes, actively participates in hormonal and inflammatory systems. Adipokines include hormones such as leptin, adiponectin, visfatin, apelin, vaspin, hepcidine, chemerin, omentin, and inflammatory cytokines, including tumor necrosis factor alpha (TNF), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator protein (PAI). Multiple roles in metabolic and inflammatory responses have been assigned to adipokines; this review describes the molecular actions and clinical significance of the more important adipokines. The array of adipokines evidences diverse roles for adipose tissue, which looms large in the mediators of inflammation and metabolism. For this reason, treating obesity is more than a reduction of excess fat; it is also the treatment of obesity’s comorbidities, many of which will some day be treated by drugs that counteract derangements induced by adipokine excesses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Von Gierke E. Ueber Fett Metabolism. Der Deutsch Ges Path. 1906;10:182–185.

    Google Scholar 

  2. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19(4):547–566. doi:10.1016/j.beem.2005.07.009.

    Article  PubMed  CAS  Google Scholar 

  3. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437–446.

    PubMed  CAS  Google Scholar 

  4. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901. doi:10.1038/29795.

    Article  PubMed  CAS  Google Scholar 

  5. Ge H, Huang L, Pourbahrami T, Li C. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem. 2002;277:45898–45903. doi:10.1074/jbc.M205825200.

    Article  PubMed  CAS  Google Scholar 

  6. Gualillo O, Eira S, Lago F, Diéguez C, Casanueva FF. Elevated serum leptin concentrations induced by experimental acute inflammation. Life Sci. 2000;67:2433–2441. doi:10.1016/S0024-3205(00)00827-4.

    Article  PubMed  CAS  Google Scholar 

  7. Blum WF, Englaro P, Hatsch S, et al. Plasma leptin levels in healthy children and adolescents: dependence on BMI, body fat mass, gender, pubertal stage, and testosterone. Clin Endocrinol Metab. 1997;82:2904–2910. doi:10.1210/jc.82.9.2904.

    Article  CAS  Google Scholar 

  8. Castracane VD, Kraemer RR, Franken MA, Kraemer GR, Gimpel T. Serum leptin concentration in women: effect of age, obesity, and estrogen administration. Fertil Steril. 1998;70:472–477. doi:10.1016/S0015-0282(98)00187-3.

    Article  PubMed  CAS  Google Scholar 

  9. Ashwin PJ, Dilipbhai PJ. Leptin and the cardiovascular system: a review. Recent Pat Cardiovasc Drug Discov. 2007;2:100–109.

    Article  PubMed  CAS  Google Scholar 

  10. Irving AJ, Wallace L, Durakoglugil D, Harvey J. Leptin enhances NR2B-mediated N-methyl-D-aspartate responses via a mitogen-activated protein kinase-dependent process in cerebellar granule cells. Neuroscience. 2006;138(4):1137–1148. doi:10.1016/j.neuroscience.2005.11.042.

    Article  PubMed  CAS  Google Scholar 

  11. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci. 1999;22:62–67. doi:10.1016/S0166-2236(98)01292-2.

    Article  PubMed  CAS  Google Scholar 

  12. Huo L, Müzberg H, Nillni EA, Bjorbaek C. Role of signal transducer and activator of transcription 3 in regulation of hypothalamic trh gene expression by leptin. Endocrinology. 2004;145:2516–2523. doi:10.1210/en.2003-1242.

    Article  PubMed  CAS  Google Scholar 

  13. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology. 1997;138:839–842. doi:10.1210/en.138.2.839.

    Article  PubMed  CAS  Google Scholar 

  14. Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19:272–277. doi:10.1185/030079903125001703.

    Article  PubMed  CAS  Google Scholar 

  15. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–770. doi:10.1038/27376.

    Article  PubMed  CAS  Google Scholar 

  16. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093–1103.

    PubMed  CAS  Google Scholar 

  17. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18:213–215. doi:10.1038/ng0398-213.

    Article  PubMed  CAS  Google Scholar 

  18. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337–350. doi:10.1016/S0092-8674(03)01081-X.

    Article  PubMed  CAS  Google Scholar 

  19. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell. 2007;131(2):242–256. 19.

    Article  PubMed  CAS  Google Scholar 

  20. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science. 2004;304:1154–1158. doi:10.1126/science.1093466.

    Article  PubMed  CAS  Google Scholar 

  21. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci. 2005;109:243–256. doi:10.1042/CS20050078.

    Article  PubMed  CAS  Google Scholar 

  22. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–290. doi:10.1016/j.bbrc.2003.07.003.

    Article  PubMed  CAS  Google Scholar 

  23. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–1101. doi:10.1016/j.bbrc.2005.06.202.

    Article  PubMed  CAS  Google Scholar 

  24. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789–5795.

    PubMed  CAS  Google Scholar 

  25. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736–740. doi:10.1161/01.CIR.0000084503.91330.49.

    Article  PubMed  CAS  Google Scholar 

  26. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199–2202. doi:10.2337/diabetes.50.10.2199.

    Article  PubMed  CAS  Google Scholar 

  27. Utzschneider KM, Carr DB, Tong J, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005;48:2330–2333. doi:10.1007/s00125-005-1932-y.

    Article  PubMed  CAS  Google Scholar 

  28. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69:76–85. doi:10.1016/j.cardiores.2005.09.015.

    Article  PubMed  CAS  Google Scholar 

  29. Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69:596–604. doi:10.1038/sj.ki.5000089.

    Article  PubMed  CAS  Google Scholar 

  30. Saito K, Tobe T, Minoshima S, et al. Organization of the gene for gelatin-binding protein. Gene. 1999;229:67–73. doi:10.1016/S0378-1119(99)00041-4.

    Article  PubMed  CAS  Google Scholar 

  31. Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8:516–523. doi:10.1038/ncb1404.

    Article  PubMed  CAS  Google Scholar 

  32. Bjursell M, Ahnmark A, Bohlooly YM, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes. 2007;65:583–593. doi:10.2337/db06-1432.

    Article  CAS  Google Scholar 

  33. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA. 2004;101:10308–10313. doi:10.1073/pnas.0403382101.

    Article  PubMed  CAS  Google Scholar 

  34. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, Type II diabetes and cardiovascular disease. Diabetes. 2007;56:1198–1209. doi:10.2337/db06-0506.

    Article  PubMed  CAS  Google Scholar 

  35. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding proteinr levels predicts the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007;115:1537–1543. doi:10.1161/CIRCULATIONAHA.106.647503.

    Article  PubMed  CAS  Google Scholar 

  36. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific proteirn, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:167–175. doi:10.1006/bbrc.1999.0255.

    Article  Google Scholar 

  37. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes. 2006;55(6):1840–1846. doi:10.2337/db05-1174.

    Article  PubMed  CAS  Google Scholar 

  38. Matsuo Y, Imanishi T, Kuroi A, et al. Effects of plasma adiponectin levels on the number and function of endothelial progenitor cells in patients with coronary artery disease. Circ J. 2007;71:1376–1382. doi:10.1253/circj.71.1376.

    Article  PubMed  CAS  Google Scholar 

  39. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promothing cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 2003;279:1304–1309. doi:10.1074/jbc.M310389200.

    Article  PubMed  CAS  Google Scholar 

  40. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006;26:224–230. doi:10.1161/01.ATV.0000194076.84568.81.

    Article  PubMed  CAS  Google Scholar 

  41. Wang Y, Lam KS, Xu JY, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280:18341–18347. doi:10.1074/jbc.M501149200.

    Article  PubMed  CAS  Google Scholar 

  42. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–175. doi:10.1111/j.1365-2796.2004.01426.x.

    Article  PubMed  CAS  Google Scholar 

  43. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–18080. doi:10.1074/jbc.M414231200.

    Article  PubMed  CAS  Google Scholar 

  44. Maturese G, Mantxoros C, La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des. 2007;13:3676–3680. doi:10.2174/138161207783018635.

    Article  Google Scholar 

  45. Kiris I, Tekin I, Yesildag A, et al. Inverse relationship between adiponectin levels and subclinical carotid athersclerosis in patients undergoing coronary artery bypass grafting. Int Heart J. 2006;47:855–866. doi:10.1536/ihj.47.855.

    Article  PubMed  CAS  Google Scholar 

  46. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292:H1655–H1663. doi:10.1152/ajpheart.01072.2006.

    Article  PubMed  CAS  Google Scholar 

  47. Lee DK, George SR, O’Dowd B. Unraveling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27:190–194. doi:10.1016/j.tips.2006.02.006.

    Article  PubMed  CAS  Google Scholar 

  48. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006;41:798–806. doi:10.1016/j.yjmcc.2006.07.004.

    Article  PubMed  CAS  Google Scholar 

  49. Atluri P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007;12:127–138. doi:10.2478/s11658-006-0058-7.

    Article  PubMed  CAS  Google Scholar 

  50. Ronkainen VP, Ronkainen JJ, Hánninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007;21:1821–1830. doi:10.1096/fj.06-7294com.

    Article  PubMed  CAS  Google Scholar 

  51. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355–360. doi:10.1016/j.ejheart.2005.10.007.

    Article  PubMed  CAS  Google Scholar 

  52. Grisk O. Apelin and vascular dysfunction in Type II diabetes. Cardiovasc Res. 2007;74:339–340. doi:10.1016/j.cardiores.2007.03.026.

    Article  PubMed  CAS  Google Scholar 

  53. Higuchi K, Masaki T, Goth K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148:2690–2697. doi:10.1210/en.2006-1270.

    Article  PubMed  CAS  Google Scholar 

  54. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430. doi:10.1126/science.1097243.

    Article  PubMed  CAS  Google Scholar 

  55. Jia S, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113:1318–1327.

    PubMed  CAS  Google Scholar 

  56. Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171:361–370. doi:10.1164/rccm.200404-563OC.

    Article  PubMed  Google Scholar 

  57. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. doi:10.1074/jbc.M008922200.

    Article  PubMed  CAS  Google Scholar 

  58. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology. 2006;131(3):788–796. doi:10.1053/j.gastro.2006.07.007.

    Article  PubMed  CAS  Google Scholar 

  59. De Souza CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56:1655–1661. doi:10.2337/db06-1506.

    Article  CAS  Google Scholar 

  60. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687–4694. doi:10.1210/en.2007-0175.

    Article  PubMed  CAS  Google Scholar 

  61. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102:10610–10615. doi:10.1073/pnas.0504703102.

    Article  PubMed  CAS  Google Scholar 

  62. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372–377. doi:10.2337/db07-1045.

    Article  PubMed  CAS  Google Scholar 

  63. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210–9213.

    PubMed  CAS  Google Scholar 

  64. Gabrielsson BG, Johansson JM, Lonn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699–708. doi:10.1038/oby.2003.100.

    Article  PubMed  CAS  Google Scholar 

  65. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type II diabetes. Nature. 2005;436:356–362.

    Article  PubMed  CAS  Google Scholar 

  66. Mandard S, Zandbergen F, van Straten E, et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasm lipid levels and adiposity. J Biol Chem. 2006;281:934–944. doi:10.1074/jbc.M506519200.

    Article  PubMed  CAS  Google Scholar 

  67. Mandard S, Zandbergen F, Tan NS, et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem. 2004;279:34411–34420. doi:10.1074/jbc.M403058200.

    Article  PubMed  CAS  Google Scholar 

  68. Wang Y, Lam KS, Lam JB, et al. Overexpression of Angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice. Mol Endocrinol. 2007;21:972–986. doi:10.1210/me.2006-0249.

    Article  PubMed  CAS  Google Scholar 

  69. Debrunner M, Schuiki E, Minder E, et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol. 2008;97:298–305. doi:10.1007/s00392-007-0626-5.

    Article  PubMed  CAS  Google Scholar 

  70. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695. doi:10.1056/NEJMra043430.

    Article  PubMed  CAS  Google Scholar 

  71. Oppenheim JJ, Feldmann M. Introduction to the role of cytokines in innate host defense and adaptative immunity. Elsevier; 2001:3–20.

  72. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch. 2006;452:418–427. doi:10.1007/s00424-006-0055-8.

    Article  PubMed  CAS  Google Scholar 

  73. Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res. 2007;39:250–255. doi:10.1055/s-2007-973075.

    Article  PubMed  CAS  Google Scholar 

  74. Mateo T, Naim Abu Nabh Y, Losada M, et al. A critical role for TNF-alpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood. 2007;110:1895–1902. doi:10.1182/blood-2007-01-070607.

    Article  PubMed  CAS  Google Scholar 

  75. Aso Y. Plasminogen activator inhibitor in vascular inflammation and thrombosis. Front Biosci. 2007;12:2957–2966. doi:10.2741/2285.

    Article  PubMed  CAS  Google Scholar 

  76. Maruyoshi H, Kojima S, Funahashi T, et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost. 2004;91:1026–1030.

    PubMed  CAS  Google Scholar 

  77. Liang X, Kanjanabuch T, Mao SL, et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab. 2006;290:E103–E113. doi:10.1152/ajpendo.00605.2004.

    Article  PubMed  CAS  Google Scholar 

  78. Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes. 2004;28:S58–S65. doi:10.1038/sj.ijo.0802858.

    Article  CAS  Google Scholar 

  79. Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol. 2004;28:443–460. doi:10.1016/j.dci.2003.09.006.

    Article  PubMed  CAS  Google Scholar 

  80. Kralisch S, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem. 2007;7:39–45. doi:10.2174/138955707779317821.

    Article  PubMed  CAS  Google Scholar 

  81. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–2466. doi:10.1161/01.CIR.0000099542.57313.C5.

    Article  PubMed  Google Scholar 

  82. Kim MP, Wahl LM, Yanek LR, Becker DM, Becker LC. A monocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population. Atherosclerosis. 2007;192:366–372. doi:10.1016/j.atherosclerosis.2006.06.029.

    Article  CAS  Google Scholar 

  83. Chabowski A, Zmijewska M, Gorski J, Bonen A, Kamiński K, Winnicka MM. Effect of IL-6 deficiency on myocardial expression of fatty acid transporters and intracellular lipid deposits. J Physiol Pharmacol. 2007;58:73–82.

    PubMed  CAS  Google Scholar 

  84. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69:164–177. doi:10.1016/j.cardiores.2005.08.017.

    Article  PubMed  CAS  Google Scholar 

  85. Nishida M, Moriyama Y, Ishii K, et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta. 2007;384:99–104. doi:10.1016/j.cca.2007.06.009.

    Article  PubMed  CAS  Google Scholar 

  86. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783.

    Article  PubMed  CAS  Google Scholar 

  87. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA

    Susan E. Wozniak, Laura L. Gee & Eldo E. Frezza

  2. Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX, USA

    Mitchell S. Wachtel

  3. New Life Bariatric, 505 N Lake Shore Drive, Suite 3101, Chicago, IL, USA

    Eldo E. Frezza

Authors
  1. Susan E. Wozniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura L. Gee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitchell S. Wachtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eldo E. Frezza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eldo E. Frezza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wozniak, S.E., Gee, L.L., Wachtel, M.S. et al. Adipose Tissue: The New Endocrine Organ? A Review Article. Dig Dis Sci 54, 1847–1856 (2009). https://doi.org/10.1007/s10620-008-0585-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0585-3

Keywords

Search

Navigation